A Scottsdale biotech company is helping to develop a spray-on bandage that could help heal wounds in hard-to-cover areas such as between fingers and toes or over joints.
ImmuneRegen BioSciences, 8767 E. Via de Ventura, has signed an agreement with BioCure, a Georgia-based medical company, to develop the liquid bandage, which backers say could facilitate more rapid healing than is possible with conventional bandages.
ImmuneRegen will contribute Homspera, a compound it has developed that contains wound-healing properties, to BioCure’s GelSpray, a spray-on liquid that forms a barrier film over a wound.
ImmuneRegen officials said Homspera may enhance the healing capability of the spray because it contains a protein that stimulates the immune system and makes cells grow faster.
“This combination of enhanced fibroblast growth and increased immune-system cells suggests a role for Homspera in improving wound and lesion healing,” said Hal Siegel, ImmuneRegen’s chief science officer.
Developed originally for military purposes, the spray-on gel is easy to apply, conforms to the wound and surrounding tissues and provides a moist protective barrier, according to BioCure. The spray is applied via a dual-cylinder syringe that enables mixing of spray streams.
The film that forms over the wound can be easily peeled off if necessary, the company said.
But it’s likely to be a while before the Homspera-enhanced GelSpray is available at your neighborhood pharmacy.
The active ingredient still must go through extensive clinical testing before it’s freed for commercial use by the Food and Drug Administration.
That could take up to three years, although it could be approved sooner for military use, said ImmuneRegen President Michael Wilhelm.
The National Institutes of Health have agreed to fund some of the studies, he said.
Wilhelm also said Homspera potentially could to be embedded in conventional bandages.
If testing goes well, the 6-year-old start-up company hopes to license Homspera to a major pharmaceutical company, he said.
BioCure co-founder and Chief Operating Officer Andrew Maslaveckas is optimistic the partnership will benefit patients.
“We believe that the combination of the technologies and experienced R and D (research and development) teams of both companies could lead to breakthrough treatments in wound healing,” he said in a statement.